In another signal of the deepening relationship between the pharma and AI sectors, Novartis chief executive Vas Narasimhan ...

Parkinson’s disease (PD) is entering a pivotal phase. For decades, treatment has centred on dopamine replacement to manage ...

Japanese pharma group Daiichi Sankyo has reached a deal to sell its consumer healthcare division to food and beverage giant ...

Infectious disease experts from around the world are calling for concerted action to combat a "silent surge" in resistance to ...

The Michael J Fox Foundation for Parkinson's Research (MJFF) has started working with Swiss biotech Biognosys on a project ...

The FDA may have approved Eli Lilly's oral weight-loss drug Foundayo in record time, but it still needs to see more safety ...

For too long, MASLD care has relied on a narrow playbook: lifestyle advice, routine monitoring, and waiting for signs of ...

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that it says brings together computational ...

Rare neurological disease has undergone a meaningful shift over the past decade. Advances in human genetics, expanded access ...

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

For now, the FDA is simply asking trial sponsors to make sure they meet the required reporting standards, but it has also ...

On today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Thomas Goetz, former executive editor of ...